Bayesian Capital Management LP Boosts Position in Twist Bioscience Co. (NASDAQ:TWST)

Bayesian Capital Management LP lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 42.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,546 shares of the company’s stock after purchasing an additional 4,352 shares during the quarter. Bayesian Capital Management LP’s holdings in Twist Bioscience were worth $499,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TWST. SG Americas Securities LLC purchased a new position in shares of Twist Bioscience during the fourth quarter worth about $619,000. Caprock Group LLC purchased a new stake in Twist Bioscience in the fourth quarter worth approximately $282,000. China Universal Asset Management Co. Ltd. boosted its stake in Twist Bioscience by 354.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,674 shares of the company’s stock worth $246,000 after buying an additional 5,204 shares in the last quarter. International Assets Investment Management LLC boosted its stake in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after buying an additional 3,907 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Twist Bioscience by 2.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after buying an additional 99,511 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $33,788.30. Following the sale, the senior vice president now owns 91,511 shares in the company, valued at $3,397,803.43. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $33,788.30. Following the sale, the senior vice president now owns 91,511 shares in the company, valued at $3,397,803.43. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 4,163 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $154,572.19. Following the completion of the sale, the chief executive officer now owns 509,986 shares in the company, valued at approximately $18,935,780.18. The disclosure for this sale can be found here. Insiders have sold 19,603 shares of company stock valued at $886,642 over the last 90 days. 3.92% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TWST. The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Robert W. Baird boosted their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Evercore ISI upped their target price on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Barclays upped their target price on Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, June 28th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $49.75.

Twist Bioscience Stock Up 0.8 %

Shares of NASDAQ TWST traded up $0.45 during trading on Wednesday, reaching $56.32. The company had a trading volume of 53,149 shares, compared to its average volume of 1,019,333. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The stock has a market cap of $3.28 billion, a PE ratio of -16.63 and a beta of 1.80. The business’s 50-day moving average is $50.07 and its 200 day moving average is $41.09.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same period last year, the firm posted ($1.06) earnings per share. Twist Bioscience’s revenue was up 25.1% compared to the same quarter last year. On average, analysts anticipate that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.